Five 503A telehealth compounding-pharmacy platforms now operate as the principal legal-channel access route for compounded GLP-1s, peptides, and HRT in the US. We audit them under a 9-dimension rubric that weights FDA history, state enforcement, sterility practice, and prescriber transparency at 60% of the composite. The current rankings: Fifty410 (6.6) leads on regulatory cleanliness, Mochi Health (6.4) leads on prescriber credentialing, Henry Meds (6.2) leads on buyer experience, Hims (6.0) is the public-company option with the most disclosure, and Trillium (5.6) has the strongest community-survey support despite the highest partner-FDA risk.
The cohort
Five 503A telehealth compounding platforms now operate at scale in the US legal channel for compounded GLP-1s and adjacent compounds. They are structurally similar but differ on the dimensions our audit methodology weights most heavily.
| Rank | Composite | Distinct signal | Platform |
|---|---|---|---|
| 1 | 6.6 | Cleanest FDA paper trail in the cohort | Fifty410 |
| 2 | 6.4 | Board-certified obesity-medicine physician model | Mochi Health |
| 3 | 6.2 | Highest Trustpilot rating, cash-pay simplicity | Henry Meds |
| 4 | 6.0 | Public-company SEC disclosure regime | Hims & Hers |
| 5 | 5.6 | Highest Reddit recommend rate, heaviest partner-FDA risk | Trillium Meds |
The composite rating is a 9-dimension weighted score covering state licensure (15%), FDA history (20%), state enforcement (15%), sterility (15%), prescriber transparency (10%), API sourcing (10%), price transparency (5%), buyer experience (5%), and buyer protection (5%). The full rubric weights and methodology are at /methodology/compounding.
How the rankings differ by dimension
Best regulatory cleanliness — Fifty410
Fifty410 (6.6/10) has the thinnest FDA paper trail of any platform in the cohort. The only confirmed partner pharmacy is BPI Labs, which carries no current FDA warning letter or 483. The "absence of evidence" caveat applies — Fifty410 doesn't publish its full partner roster — but the public-record FDA history is the cleanest of the five. Highest Trustpilot rating in the cohort at 4.7/5 across roughly 4,000 reviews.
Best prescriber credentialing — Mochi Health
Mochi Health (6.4/10) is led by Dr. Myra Ahmad, board-certified in obesity medicine, with a public Providers page listing credentialed physicians and their ABOM status. This is the strongest prescriber-transparency signal in the cohort — Hims and Henry publish corporate-medical-director names at most, not a credentialed physician roster. Mochi also runs a pediatric obesity-medicine vertical, which is unique in the cohort. Membership-based pricing model ($79/mo standard, $39 first-month promo, separate from medication cost).
Best buyer experience — Henry Meds
Henry Meds (6.2/10) has the highest Trustpilot rating among the platform-scale players (4.6/5 across ~9,500 reviews) — one full point above Hims at 3.8. The "no insurance, no waiting rooms" cash-pay model produces less subscription friction than Hims's bundled platform. Multi-vertical (GLP-1, women's HRT, testosterone, ED, phentermine). Private company, so SEC disclosure isn't part of the verifiable record.
Best disclosure transparency — Hims & Hers Health
Hims (6.0/10) is the only publicly-traded platform in the cohort, which means quarterly SEC filings, audited financials, earnings-call disclosures, and shareholder-litigation records are part of the verifiable record. The Novo Nordisk partnership-termination dispute in mid-2025 is a real regulatory-history drag specific to Hims that no other platform carries. Largest scale by customer count.
Most popular among Reddit users — Trillium Meds
Trillium (5.6/10) has the highest community-survey recommend rate (93% on the May 2026 r/Tirzepatidecompound survey) despite the lowest composite audit score. The composite is dragged by the primary partner pharmacy Hallandale (Pharmcore Inc.), which has a documented 2020 FDA warning letter for insanitary sterile compounding plus multiple 483 inspection observations through 2025. The popularity-vs-audit divergence is the editorial spine of our v0 pharmacy-vertical research.
What every platform shares
All five operate under the same post-shortage "clinical-need personalization" pathway under FDA 503A rules. The FDA's public position is that personalization must be tied to documented clinical need, not used as a marketing pathway around the shortage rule. This regulatory cloud applies equally to every platform in the cohort. We covered the broader regulatory backstory in 503A and the PCAC: how compounding restrictions closed the legal GLP-1 market and compounded semaglutide in 2026: where the legal channel actually stands.
None of the five platforms has a current FDA warning letter against the platform itself. All carry the same prospective regulatory exposure on the personalization pathway.
How to choose between them
The honest read is that "which is best" depends on what you optimize for.
Optimizing for lowest regulatory risk on the actual fill → Fifty410. Thinnest partner-FDA paper trail in the cohort.
Optimizing for strongest medical oversight → Mochi Health. Board-certified obesity-medicine physicians with a published roster.
Optimizing for cash-pay simplicity and best buyer experience → Henry Meds. No insurance friction, no quote-walls, highest Trustpilot per platform-scale operator.
Optimizing for the most disclosure-transparent operator → Hims. SEC filings, earnings calls, public Novo dispute documentation, all in the verifiable record.
Optimizing for community-survey support → Trillium. But know the partner-pharmacy FDA history.
What this comparison does NOT measure
Three honest limitations.
No first-hand vialaudit consults yet. The audit reads public records, not vial-in-hand testing. A full audit tier for any of these platforms would include a first-hand consult, named-prescriber NPI verification, partner-pharmacy state-license cross-checks, and ideally a third-party lab test on the actual fill.
Per-fill pharmacy disclosure is universally weak. None of the five platforms surfaces the specific dispensing pharmacy at checkout. A buyer signs up not knowing which 503A facility will fill their prescription.
Post-shortage regulatory trajectory is unsettled. The FDA's posture on the "personalized compounding" pathway has continued to harden through 2025-2026. The composite scores assume the current regulatory frame holds. If the FDA further restricts the personalization exception, all five composites would drop.
Related reading
- /pharmacies — the canonical cohort index with side-by-side scoring.
- Methodology - compounding pharmacies — full audit rubric.
- 503A and the PCAC: GLP-1 compounding restrictions — regulatory backstory.
- Compounded semaglutide in 2026 — state of the legal channel.
- Longevity peptides 2026 — companion article on the compounds these platforms dispense.
Sources
- Individual pharmacy audit pages on this site (linked above)
- FDA Compounding Inspections, Recalls, and Other Actions database
- r/Tirzepatidecompound May 2026 monthly telehealth and pharmacy survey
- Trustpilot profile-level data per platform
- Public SEC filings (Hims & Hers Health, NYSE - HIMS)
Frequently asked
What is a longevity telehealth platform?
A telehealth platform that uses the 503A compounding-pharmacy pathway to dispense personalized formulations of GLP-1s, peptides, hormone replacement, and other longevity-adjacent compounds. The model emerged in 2023-2024 during the FDA shortage discretion for semaglutide and tirzepatide and persists post-shortage under the "clinical-need personalization" exception. Five of these platforms now have enough scale to be the audited cohort.
Which longevity telehealth platform is the best?
No single answer - the audit rubric measures different dimensions and different buyers should optimize different ones. Fifty410 has the cleanest FDA paper trail at 6.6/10. Mochi Health has the strongest prescriber credentialing at 6.4/10. Henry Meds has the best buyer-experience signal at 6.2/10. Hims (6.0/10) is the only public-company option with SEC-disclosure transparency. Trillium (5.6/10) has the highest Reddit recommend rate but the heaviest partner-FDA risk.
Are these platforms safe to use?
All five operate FDA-registered 503A facilities under state-pharmacy-board oversight. None has a current FDA warning letter against the platform itself, though Trillium's primary partner pharmacy Hallandale has a documented FDA warning-letter history. The structural regulatory question is whether the post-shortage "personalized compounding" pathway holds up under continuing FDA scrutiny - this risk applies to the entire cohort, not to any single platform.
Can I use insurance with these platforms?
Only Mochi Health accepts commercial insurance for the medication path. The other four (Trillium, Fifty410, Hims, Henry Meds) operate cash-pay models. The membership/subscription pricing structures vary - some bundle the platform fee with medication, some itemize separately. We cover each model in the per-platform audit.
How does this compare to buying research-grade peptides?
Different legal frame entirely. The 503A telehealth platforms produce compounded drugs under FDA-recognized pharmacy regulation and are prescribed by licensed clinicians for documented clinical need. Research-peptide vendors sell research-use-only material with COAs but no prescriber requirement and no FDA-approved indication. The 503A channel is more expensive but legally distinct.